EuroNanoMed (ENM) is an ERA-NET on Nanomedicine established since 2008 as a platform for funding agencies and ministries to coordinate research programmes with the goal of creating and funding collaborative research projects that can convert research in nanotechnology into practical gains in medicine. Through 7 successful Joint Transnational Calls launched from 2009 to 2016, EuroNanoMed has allocated about 55 Million euros to fund 60 transnational projects in nanomedicine.
Under the umbrella of EuroNanoMed III, the 8th Joint Transnational Call is now opened for funding multilateral innovative research projects on nanomedicine together with the European Commission under the ERA-NET Cofund mechanism:
In this 8th EuroNanoMed call 126 eligible pre-proposals were submitted. A total of 58 peer reviewers from 19 different countries have participated in the evaluation process. Based on the peer reviewers’ scores, recommendations and the availability of funds from the participating funding organisations, the Call Steering Committee decided to request a full proposal from 39 consortia. This number of selected proposals represents 2.2 times the available funding.
Research project consortia who invited to submit a transnational full-proposal should register as soon as possible and submit the proposal from May 5th to June 9th. This can be done at https://secure.pt-dlr.de/ptoutline/app/euronanomed2017, by clicking on “to register” and following instructions. Electronic proposal submission of proposals on the indicated website is mandatory.
Contact details for the Joint Call Secretariat:
JCS is hosted by the French National Research (ANR)
Postal Address: 50 avenue Daumesnil, 75012 PARIS – France
Contact person for the Joint Call Secretariat: Amélie Vergne
ENMCalls@anr.fr ; +33 (0)1 78 09 80 44
Call related documents:
(Please note that the Guidelines for applicants have been updated on pages 20 and 21 – “Ireland information for applicants”)
Looking for partners?
See the Nanomed Map: http://www.etp-nanomedicine.eu/public/nanomedmap/
And our partner search tool: https://www.euronanomed.net/partner-search/list-of-searches-and-offers/
EuroNanoMed aims (i) to support translational research projects that combine innovative approaches in the field of nanomedicine and; (ii) to encourage and enable transnational collaboration between public and private research groups from academia, clinical/public health research or research teams from industrial enterprises (all size). The participation of Medical Doctors and SMEs will be strongly encouraged.
Project proposals will address multidisciplinary and translational research. Project proposals will need to cover at least one of the following areas that are equal in relevance for this call:
The projects should fall within Technology Readiness Levels (TRL)[1] 3-6, although for being realistic and coherent with the characteristics of the call, projects should propose advancements for a maximum of two TRL levels during their lifetime.
A consortium applying to this call will be required to include research group(s) from at least 2 of the 3 following categories, if eligible according to relevant national/regional funding organisations’ regulations for research funding[1]:
Please note! Whilst applications will be submitted jointly by groups from several countries, individual groups will be funded by the individual EuroNanoMed III funding organisation respective of the country/region from which applicants have applied. The applications are therefore subjected to eligibility criteria of individual funding organisations. Applicants are strongly advised to contact their national representatives as soon as possible in order to confirm with their eligibility.
Only transnational projects will be funded. Each consortium submitting a proposal will need to involve a minimum of 3 eligible and a maximum of 5 eligible partners from at least 3 different countries participating to the call (see list below) though no more than 2 eligible partners from the same country participating in the call will be accepted in one consortium.
Research groups not eligible to be funded (e.g. from non-funding countries or not fundable according to national/regional regulations of the participating funding countries) may participate in transnational projects if they are able to secure their own funding. However, no more than one research group with own funding can be included in a consortium and the coordinator must be eligible to be funded by EuroNanoMed III participating countries/regions.
The maximum number of partners will possibly be increased from 5 to 7 (including eligible for funding and non-eligible for funding research groups) if partners from these participating countries, which are either new in the EuroNanoMed consortium or their community has been under-represented in past EuroNanoMed calls: Belgium, Estonia, Ireland, Latvia, Lithuania, Romania, Slovakia, Taiwan, and Turkey (see table below).
Number of partners requesting funding (eligible partners) | 3 | 4 | 5 | 6
(only with at least one underrepresented) |
7
(only with at least 2 underrepresented) |
Possible number of additional partners with own funding | 1 | 1 | 1 | 1 | 0 |
Belgium / French speaking community, Canada (Quebec), Estonia, France, Germany, Greece, Ireland, Israel, Italy, Latvia, Lithuania, Netherlands, Norway, Poland, Romania, Slovakia, Spain, Taiwan and Turkey (contact list is provided below).
Please note:
Country | Funding Organisation | Contact point | |
Belgium | FNS-FNRS | Arnaud Goolaerts | arnaud.goolaerts@frs-fnrs.be |
Canada (Québec) | FRQS | Karine Genest
Anne-Cécile Desfaits |
Karine.genest@frq.gouv.qc.ca |
Estonia | ETAg | Aare Ignat | Aare.ignat@etag.ee |
France | ANR | Amélie Vergne | ENMCalls@anr.fr |
Germany | VDI Technologiezentrum GmbH | Alexandra Brennscheidt | brennscheidt@vdi.de |
Greece | GSRT | Paraskevi Afentaki | pafe@gsrt.gr |
Ireland | SFI | Louise Rocks | louise.rocks@sfi.ie |
Israel | CSO-MOH | Irit Allon | Irit.allon@moh.gov.il |
Italy | IMH | Gaetano Guglielmi | g.guglielmi@sanita.it |
Italy | MIUR | Aldo Covello
Andrea Pompozzi |
aldo.covello@miur.it |
Latvia | VIAA | Linda Vecbiskena | Linda.Vecbiskena@viaa.gov.lv |
Lithuania | RCL | Laura Kostelnickienė | laura.kostelnickiene@lmt.lt |
The Netherlands | STW | Melvin Kasanrokijat | m.kasanrokijat@stw.nl |
Norway | RCN | Cecilie A. Mathiesen | cam@rcn.no |
Poland | NCBR | Aleksandra Mościcka-Studzińska | aleksandra.moscicka@ncbr.gov.pl |
Romania | UEFISCDI | Mihaela Manole | mihaela.manole@uefiscdi.ro |
Slovakia | SAS | Katarina BIBOVA
Jan BARANCIK |
bibova@up.upsav.sk |
Spain | MINECO | Carles Cané
Leonor Gómez |
era-nano@mineco.es |
Spain | ISCIII | María Druet | mdruet@isciii.es |
Spain | CDTI | Juan Luis Romera | juanluis.romera@cdti.es |
Taiwan | MOST | Louis Chen | ymchen@most.gov.tw |
Turkey | TUBITAK | Mahmut OZER | mahmut.ozer@tubitak.gov.tr |
[1] Horizon 2020 scale for TRL:
Ⓒ All rights reserved EuroNanoMed III, 2018